TMCnet News
Philips receives FDA 510(k) clearance to market multiple new applications on its IntelliSpace Portal platform for RadiologyAMSTERDAM, June 27, 2017 /PRNewswire/ -- Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market IntelliSpace Portal 9.0 and a range of innovative applications for Radiology in the U.S. The latest release of Philips' clinical informatics platform for advanced visual analysis and quantification of medical images now offers enhanced additional applications for Longitudinal Brain Imaging and Multi-Modality Tumor Tracking, as well as optimized Lung Nodule Assessment. IntelliSpace Portal 9.0 has been available outside of the U.S. since November 2016 and will be available in the world's largest healthcare market as of this month. Quantify and quickly diagnose conditions The number of people diagnosed with cancer and chronic diseases such as Cardiovascular Disease, COPD and Dementia continues to rise. Timely diagnosis and early intervention can improve patient outcomes. These conditions also require longer term treatment and continued follow-up to monitor a patient's response to a chosen therapy over time and define the next steps in the treatment process. "Analytics applications optimized for clinical decision support and longitudinal and quantified patient tracking are becoming increasingly important to radilogists," said Mark van Buchem, professor of neuroradiology at the Leiden University Medical Center, one of the development partners of IntelliSpace Portal 9.0. "They can help visualize and quantify very subtle manifestations of disease and differences over time that may not be seen with the naked eye. IntelliSpace Portal 9.0 integrates into our existing workflow and adds greatly to our patient care." "IntelliSpace Portal shows how we continuously innovate to help clinicians achieve first-time-right diagnoses, track disease development, and improve patient care," said Yair Briman, Business Leader Healthcare Informatics at Philips. "Together with clinical partners we develop solutions that help add depth and insight to a physician's diagnosis. Our newest clinical informatics innovations can now be used to help streamline care for more and even the most complex patients." Evaluation of brain disorders over time Proprietary qEASL technology for oncology About Royal Philips [1] quantitative European Association for the Study of the Liver For further information, please contact: Kathy O'Reilly Joost Maltha To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/philips-receives-fda-510k-clearance-to-market-multiple-new-applications-on-its-intellispace-portal-platform-for-radiology-300480145.html SOURCE Royal Philips |